Capricor Therapeutics (CAPR) Net Cash Flow (2010 - 2026)

Capricor Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$182.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 1141.99% year-over-year to -$182.4 million; the TTM figure through Mar 2026 stood at $76.6 million (up 239.36% YoY), while the FY2025 annual figure was $276.6 million, up 8215.36% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$182.4 million, down from $268.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $268.3 million in Q4 2025, with the low at -$182.4 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$768395.0 (2023), against an average of $4.1 million.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow surged 6867.31% in 2024, then slumped 1141.99% in 2026.
• Capricor Therapeutics' Net Cash Flow stood at $1.2 million in 2022, then soared by 380.01% to $5.7 million in 2023, then plunged by 1099.8% to -$57.1 million in 2024, then jumped by 570.02% to $268.3 million in 2025, then sank by 167.98% to -$182.4 million in 2026.
• Business Quant data shows CAPR's Net Cash Flow at -$182.4 million in Q1 2026, $268.3 million in Q4 2025, and -$3.7 million in Q3 2025.